TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6738937
Drug: Long-acting prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting prostaglandin suppository (9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2)
Study: 31478290
Drug: Cuminum cyminum
Normalized name: CUMINUM CYMINUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuminum cyminum L. essential oil (CuEO) 75 mg, thrice daily for 8 weeks
Study: 31478290
Drug: Placebo soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo soft gel, thrice daily for 8 weeks
Study: 25546488
Drug: Multidisciplinary group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary group-based rehabilitation program plus oral medication
Study: 19246733
Drug: Cephradine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine (500 mg)
Study: 19246733
Drug: Captopril and
Normalized name: captopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril and Cephradine co-administration
Study: 10505743
Drug: IFN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN therapy
Study: 8726600
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with lovastatin 20 mg/day and niacin 500 mg 3 times/day
Study: 6465160
Drug: Aspirin (2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2,400 and 3,900 mg/day)
Study: 7234826
Drug: Ibuprofen (2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2,400 mg/day)
Study: 6465160
Drug: Ibuprofen (1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1,600 mg/day for three days)
Study: 6465160
Drug: Ibuprofen (4,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (4,800 mg/day)
Study: 6465160
Drug: Naproxen, tolmetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, tolmetin sodium, indomethacin (larger doses)
Study: 6465160
Drug: Placebo, pro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, pro drugs, enteric-coated aspirin
Study: 24769600
Drug: Procarbazine, lomustine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procarbazine, lomustine, and vincristine (PCV) chemotherapy combined with standard radiation therapy (RT)
Study: 24769600
Drug: Standard course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard course of radiation therapy (RT)
Study: 20377116
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg once daily for 2 weeks
Study: 8923037
Drug: Anticarcinogenic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticarcinogenic agent (specific agent not mentioned)
Study: 1909810
Drug: Oral natural
Normalized name: Nature-Throid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral natural micronized progesterone
Study: 22466821
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (V(T) 5 ml kg(‐1)) with high PEEP
Study: 22466821
Drug: Larger tidal
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger tidal volume (V(T) 8 ml kg(‐1)) with low PEEP
Study: 20880345
Drug: Ezetimibe/simvastatin (E/S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin (E/S) + extended-release niacin (N)
Study: 10515518
Drug: Delayed-treatment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment group (Control)
Study: 8746601
Drug: Triglycerides, HDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglycerides, HDL cholesterol, and insulin variables
Study: 2042788
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) infusion (7 mg/kg bolus followed by 10 mg/kg/h continuous infusion)
Study: 2042788
Drug: Concurrent MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concurrent MgSO4 and epinephrine administration
Study: 7266894
Drug: E.N.L. protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E.N.L. protocol (erythromycin + neomycin + 600 mg lincomycin 1 hr prior to surgery)
Study: 31552526
Drug: Omalizumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (150 mg) administered as a single subcutaneous injection 2 weeks postoperatively.
Study: 31552526
Drug: Intranasal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroids (budesonide or mometasone furoate, 100 μg twice daily for 6 months) starting 2 weeks postoperatively.
Study: 31418855
Drug: 25 milligrams
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 milligrams cobalt intravenously as CoCl2 weekly
Study: 31418855
Drug: 50 milligrams
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 milligrams cobalt intravenously as CoCl2 weekly
Study: 31418855
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cobalt administration)
Study: 26082975
Drug: Albu‐BChE (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albu‐BChE (50, 100, and 300 mg)
Study: 16756038
Drug: Intracutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injections of 0.1 mL sterile water (n = 25)
Study: 10780760
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone dipropionate (1.5 mg daily)
Study: 7693425
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy consisting of fluorouracil, epirubicin plus cyclophosphamide (FEC) for 6 cycles
Study: 31927162
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing plus Cognitive Behavior Therapy (MI/CBT)
Study: 30195996
Drug: Intermittent sulfadoxine‐pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sulfadoxine‐pyrimethamine (two doses of 1500 mg sulfadoxine and 75 mg pyrimethamine, 4 weeks apart)
Study: 30195996
Drug: Intermittent chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent chloroquine (two doses of 600 mg on day 1, 600 mg on day 2, and 300 mg on day 3)
Study: 30195996
Drug: Chloroquine prophylaxis
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine prophylaxis (600 mg on day 1 then 300 mg every week)
Study: 26276501
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg HDC
Study: 26276501
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg HDC
Study: 23855761
Drug: Tofacitinib 2
Normalized name: tofacitinib 22 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 2 mg
Study: 16962881
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg and 80 mg (combined analysis)
Study: 15290426
Drug: Plantar-calf sequential
Normalized name: thymus gland-calf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantar-calf sequential compression device
Study: 11426356
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with intravenous morphine (n = 15)
Study: 7868100
Drug: Postpartum monitoring
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postpartum monitoring plus medication (either previously effective medication or nortriptyline)
Study: 2508567
Drug: Regimen C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C: MMC 12 mg/m2 i.v. at operation day and 6 mg/m2 in every 2 months + UFT 600 mg/day p.o.
Study: 2508567
Drug: Regimen D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen D: MMC 12 mg/m2 i.v. at operation day and 6 mg/m2 in every 2 months + UFT 400 mg/day p.o.
Study: 789082
Drug: Propranolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (up to 480 mg daily)
Study: 789082
Drug: Atenolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (up to 600 mg daily)
Study: 31264764
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (LY2963016)
Study: 24133024
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears (0.1% sodium hyaluronate solution, five times daily)
Study: 16443860
Drug: Nicorandil (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (12 mg intravenously before reperfusion)
Study: 10804076
Drug: Regular doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular doses of nortriptyline (60 mg-80 mg/day)
Study: 10804076
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of nortriptyline (10 mg-13 mg/day)
Study: 8960488
Drug: Intraligamental injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamental injection
Study: 8507417
Drug: Cotrimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole) twice a day on Mondays, Wednesdays and Fridays (n = 81)
Study: 8507417
Drug: Dapsone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (100 mg) plus pyrimethamine (25 mg) once a week (n = 85)
Study: 28731885
Drug: Sleeper stretch
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleeper stretch daily for 8 weeks
Study: 24403477
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (30 mg of elemental zinc/day for eight weeks)
Study: 21383341
Drug: Effervescent ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Effervescent ibuprofen (400 mg)
Study: 21383341
Drug: Standard ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ibuprofen (Nurofen(®) 2 × 200 mg)
Study: 12576370
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of epinephrine, 1.5 mg, in 4 mL of 3% saline solution (group 2; n = 27)
Study: 12576370
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of epinephrine, 1.5 mg, in 4 mL of 0.9% saline solution (group 1; n = 25)
Study: 8594240
Drug: Zidovudine therapy
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine therapy during pregnancy and/or during labor and delivery
Study: 8594240
Drug: Zidovudine therapy
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine therapy during gestation
Study: 8487326
Drug: Methotrexate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (60 mg/m2) and Fluorouracil (600 mg/m2) (MF)
Study: 8487326
Drug: Cyclophosphamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (100 mg/m2) orally on days 1‐14 plus MF (CMF)
Study: 3031714
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg ACTH 4-10
Study: 27680029
Drug: Intrauterine 500
Normalized name: Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine 500 IU hCG in up to 0.5 ml normal saline
Study: 27680029
Drug: Intrauterine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine 0.5 ml normal saline
Study: 18217157
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg LD / 75 mg MD
Study: 15452187
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 U subcutaneous weekly for 16 weeks
Study: 15452187
Drug: Nonresponders (irrespective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders (irrespective of treatment arm)
Study: 10811451
Drug: 131I-MAb-LL2 administered
Normalized name: iobenguane (131I)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 131I-MAb-LL2 administered in a twice weekly pattern with 20 mg of unlabeled LL2 prior to each dose
Study: 8897877
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron (5‐HT3 antagonist)
Study: 1808368
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of Self Reinforcement after External-Self Dual Reinforcement (delta SR)
Study: 1808368
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of External Reinforcement following Dual Reinforcement (delta ER)
Study: 1808368
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of External-Self Dual Reinforcement (delta ESR)
Study: 6800270
Drug: Amitriptyline tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline tapering and discontinuation (double-blind)
Study: 6800270
Drug: Amitriptyline tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline tapering and discontinuation
Study: 31351660
Drug: Cligosiban 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 400 mg
Study: 31351660
Drug: Cligosiban 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 800 mg
Study: 31351660
Drug: Cligosiban 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cligosiban 1200 mg
Study: 28204722
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg, titrated intravenously)
Study: 28204722
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg additional)
Study: 25691036
Drug: Deferasirox treatment
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox treatment for 1 year
Study: 11475442
Drug: IFN-beta-1a 30
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-beta-1a 30 mcg
Study: 11475442
Drug: IFN-beta-1a 60
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-beta-1a 60 mcg
Study: 7989637
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MIF‐1 (Pro‐Leu‐Gly‐NH2)
Study: 2465562
Drug: Histaglobin-Triplex (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histaglobin-Triplex (combination of histamine and human gammaglobulin)
Study: 30508293
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL water drink
Study: 30508293
Drug: 330 mL
Normalized name: ALCOHOL 247.5 mL in 330 mL EXTRACORPOREAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 mL water drink
Study: 28051800
Drug: Lactulose (30-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (30-120 mL/day)
Study: 24184427
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy
Study: 31754063
Drug: Living with
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living with both biological parents
Study: 10859283
Drug: abciximab-reteplase 5+5
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab-reteplase 5+5 U with 60 U/kg heparin
Study: 10859283
Drug: abciximab-reteplase 5+5
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab-reteplase 5+5 U with 40 U/kg heparin
Study: 10859283
Drug: low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose heparin
Study: 8247594
Drug: Glucomannan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (1 g twice a day for two months)
Study: 3756056
Drug: Inhaled nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrous oxide with i.v. fentanyl increments
Study: 27253380
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review intervention
Study: 20157745
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg raloxifene and 1 microg alfacalcidol (RA)/day
Study: 18601844
Drug: Single Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Chinese herbal medicine‐based intervention
Study: 18601844
Drug: Active compound‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active compound‐based TCM drug intervention
Study: 1378646
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nomegestrol acetate combined with 17-beta-estradiol by transcutaneous route
Study: 6389217
Drug: Hydrocortisone 17-butyrate
Normalized name: Cortisol 17-butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 17-butyrate (Locoid) 0.1% cream
Study: 6389217
Drug: Hydrocortisone (Uniderm)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (Uniderm) 1% cream
Study: 29685482
Drug: Personalized physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized physical therapy
Study: 20408890
Drug: Complete immunization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete immunization schedule with commercial vaccines
Study: 17505460
Drug: Corticosteroids administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroids administration (antepartum or postpartum)
Study: 17505460
Drug: Corticosteroids administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroids administration
Study: 7881669
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 150 mg.kg‐1 in 250 ml 5% dextrose intravenously over 15 min
Study: 7881669
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in 250 ml 5% dextrose intravenously over 15 min
Study: 2404433
Drug: Rynatan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rynatan (8 mg chlorpheniramine tannate, 25 mg pyrilamine tannate, 25 mg phenylephrine tannate)
Study: 39233
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 100 mg Betadrenol daily for three days
Study: 39233
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 100 mg Betadrenol daily for ten days
Study: 28202770
Drug: Daptomycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (5 mg/kg for 12-17 years, 7 mg/kg for 7-11 years, 9 mg/kg for 2-6 years, 10 mg/kg for 12-23 months)
Study: 28202770
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) treatment (primarily clindamycin or vancomycin)
Study: 25611207
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg daily for 1 week)
Study: 22886783
Drug: Elevated CRP
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated CRP (≥2 mg/L)
Study: 22886783
Drug: No elevated
Approvals — FDA: no, EMA: no, PMDA: no
Description: No elevated CRP (<2 mg/L)
Study: 19440073
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement (200 mg of testosterone cypionate intramuscular injections every 10 days)
Study: 25427171
Drug: Zonisamide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (400 mg/d)
Study: 26623405
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron (Group O)
Study: 11578887
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide (Group M)
Study: 11578887
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL normal saline (Group P)
Study: 7930025
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at concentrations of 100-2000 ppb
Study: 26008690
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine (DAC) alone
Study: 26008690
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine (DAC) in combination with valproic acid (VPA)
Study: 26008690
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine (DAC) in combination with all-trans retinoic acid (ATRA)
Study: 26008690
Drug: Low-dose decitabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose decitabine (DAC) in combination with both VPA and ATRA
Study: 11411653
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine (Nicorette® chewing gum)
Study: 7911147
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin
Study: 7911147
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g piperacillin
Study: 25140958
Drug: Bedaquiline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline (400 mg once daily for 2 weeks, followed by 200 mg three times a week for 22 weeks)
Study: 20529368
Drug: Comprehensive assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive assessment including in-home interview, self-administered questionnaire, medical/dental examination.
Study: 9641689
Drug: Low-dose lamifiban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lamifiban (1 microg/min)
Study: 9641689
Drug: High-dose lamifiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lamifiban (5 microg/min)
Study: 9641689
Drug: High-dose lamifiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lamifiban and heparin
Study: 9641689
Drug: Low-dose lamifiban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lamifiban and heparin
Study: 9641689
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (placebo and heparin)